<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We present the case of a 35-year-old woman with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> who developed an Epstein-Barr virus (EBV)-induced B-cell lymphoproliferation with secondary <z:mp ids='MP_0001799'>viral</z:mp>-induced <z:e sem="disease" ids="C0876991" disease_type="Disease or Syndrome" abbrv="">hemophagocytosis</z:e> 13 months after treatment with rituximab and CHOP (<z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>/<z:chebi fb="0" ids="28748">doxorubicin</z:chebi>/<z:chebi fb="0" ids="28445">vincristine</z:chebi>/<z:chebi fb="0" ids="8382">prednisone</z:chebi>) chemotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>The EBV-induced lymphoproliferation was successfully treated with single-agent rituximab </plain></SENT>
<SENT sid="2" pm="."><plain>To our knowledge, this is the first such case reported in the literature </plain></SENT>
<SENT sid="3" pm="."><plain>Herein, we briefly review the spectrum of <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo>-associated <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> (LPDs), discuss the immune deficit induced by rituximab, and speculate on its possible association with EBV reactivation in this patient </plain></SENT>
</text></document>